Healthcare Industry News: Novogyne
News Release - June 30, 2008
Noven Names Anthony Venditti Vice President - Marketing & SalesMIAMI--(HSMN NewsFeed)--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN ) today announced the appointment of senior pharmaceutical executive Anthony Venditti as its Vice President – Marketing & Sales, effective immediately. In this role, Venditti will lead all aspects of the marketing and sales functions at Noven Therapeutics (the company’s specialty pharmaceutical business unit) and Novogyne Pharmaceuticals (the company’s joint venture with Novartis Pharmaceuticals Corporation).
Venditti joins Noven with over 20 years of pharmaceutical marketing and sales experience. Most recently, he served Novartis Pharmaceuticals Corporation as Vice President and head of Novartis’ $1.3 billion U.S. Neuroscience division, where he was responsible for marketing, sales and new product operations for the central nervous system (CNS) portfolio in the U.S. Previously, he served Novartis in a number of senior executive positions, with responsibility for marketing, sales, business analysis, strategic planning and new product commercialization, including key roles in the launch of several new products.
“Anthony will direct both the marketing and the sales functions at Noven Therapeutics and Novogyne,” said Peter Brandt, Noven’s President & Chief Executive Officer. “He has a history of success in marketing and sales, expertise in CNS and other therapeutic areas, and significant experience with new product launches – all of which make him a great fit with our growth strategy. He is a proven industry veteran who I expect will help lead Noven’s evolution from primarily a drug delivery company to a high growth specialty pharmaceutical company.”
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s business and operations are focused in three principal areas – transdermal drug delivery, the Novogyne joint venture, and its Noven Therapeutics specialty pharmaceutical unit.
Source: Noven Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.